Morgan Stanley (NYSE:MS) initiated coverage on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care and other serious chronic conditions. The ...
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
The settlement filed in Newark, N.J. federal court comes after similar settlements with Eli Lilly and Sanofi last year. It ...
On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its ...
We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
According to Novo Nordisk, over 40% of persons with type 2 diabetes have chronic renal disease, which affects roughly 37 million adults in the United States. Last year, the FDA authorized Wegovy ...
Roughly 40% of Type 2 diabetes patients have the condition, which can cause additional sickness such as increased risk of cardiovascular problems and death, Novo Nordisk said. "All chronic kidney ...
The Danish drug giant Novo Nordisk, known for its antidiabetes and weight loss drugs ... It said that this was due to a problem with its vendor tagging system.2 ...
He urged party workers to ensure transparency while inducting new members, and “avoid admitting individuals with a tainted image”. While claiming that state government had allocated Rs 3,700 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback